PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34496956-10	2021	Blocking the activity of GluN2B-NMDARs at the soma completely reversed both the TBOA-induced or the Abeta1-42-induced somatic potentiation and neuronal hyperactivity.	benzyloxyaspartate	80-84	glutamate ionotropic receptor NMDA type subunit 2B	Homo sapiens	25-31
34811469-8	2021	Both FC- and TFB-TBOA-mediated synaptic depression were inhibited in brain slices pre-treated with the dopamine D2 receptor antagonist sulpiride, but insensitive to agents acting on presynaptic glutamatergic autoreceptors, NMDA receptors, gap junction coupling, cannabinoid 1 receptors, micro-opioid receptors, P2 receptors or GABAA receptors.	benzyloxyaspartate	17-21	dopamine receptor D2	Homo sapiens	103-123
32008166-7	2020	In contrast, artificial suppression of GLT1 activity by DL-threo-beta-benzyloxyaspartate (DL-TBOA) in naive rats induced synaptic C1q expression and microglial phagocytosis of glutamatergic synapses in the hippocampal CA1 area, resulting in synaptic and cognitive dysfunction.	benzyloxyaspartate	56-88	solute carrier family 1 member 2	Rattus norvegicus	39-43
35091501-4	2022	Among the 5 GLT inhibitors we tested, TFB-TBOA was the most potent.	benzyloxyaspartate	42-46	solute carrier family 1 member 3	Rattus norvegicus	12-15
35091501-7	2022	The reduction in cocaine self-administration following TFB-TBOA administration was NMDA GluN2B receptor-dependent, and rats self-administering cocaine showed upregulation of GluN2B expression in NAc DARPP32 (DA- and cAMP-regulated phosphoprotein)-positive medium-spiny neurons.	benzyloxyaspartate	59-63	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	88-94
35091501-7	2022	The reduction in cocaine self-administration following TFB-TBOA administration was NMDA GluN2B receptor-dependent, and rats self-administering cocaine showed upregulation of GluN2B expression in NAc DARPP32 (DA- and cAMP-regulated phosphoprotein)-positive medium-spiny neurons.	benzyloxyaspartate	59-63	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	174-180
35091501-7	2022	The reduction in cocaine self-administration following TFB-TBOA administration was NMDA GluN2B receptor-dependent, and rats self-administering cocaine showed upregulation of GluN2B expression in NAc DARPP32 (DA- and cAMP-regulated phosphoprotein)-positive medium-spiny neurons.	benzyloxyaspartate	59-63	protein phosphatase 1, regulatory (inhibitor) subunit 1B	Rattus norvegicus	199-206
35091501-12	2022	Here we report that TFB-TBOA, a highly potent glutamate transporter inhibitor, dose-dependently elevates extracellular glutamate and inhibits cocaine self-administration and brain-stimulation reward, when administered locally into the NAc, but not other brain regions.	benzyloxyaspartate	24-28	solute carrier family 1 member 3	Rattus norvegicus	46-67
35091501-13	2022	Mechanistic assays indicate that cocaine self-administration upregulates NMDA-GluN2B receptor subtype expression in striatal dopaminoceptive neurons and activation of GluN2B by TFB-TBOA-enhanced glutamate inhibits cocaine self-administration.	benzyloxyaspartate	181-185	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	78-84
35091501-13	2022	Mechanistic assays indicate that cocaine self-administration upregulates NMDA-GluN2B receptor subtype expression in striatal dopaminoceptive neurons and activation of GluN2B by TFB-TBOA-enhanced glutamate inhibits cocaine self-administration.	benzyloxyaspartate	181-185	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	167-173
32008166-7	2020	In contrast, artificial suppression of GLT1 activity by DL-threo-beta-benzyloxyaspartate (DL-TBOA) in naive rats induced synaptic C1q expression and microglial phagocytosis of glutamatergic synapses in the hippocampal CA1 area, resulting in synaptic and cognitive dysfunction.	benzyloxyaspartate	90-97	solute carrier family 1 member 2	Rattus norvegicus	39-43
30364232-9	2018	In the presence of the glutamate transporter blocker TBOA (30 muM), the D-AP5-sensitive current was also significantly less in Grin2D-null mice.	benzyloxyaspartate	53-57	eukaryotic translation initiation factor 4, gamma 2	Mus musculus	72-77
30905632-3	2019	TB1 elicits CD4 T-cell response, and TB2 elicits both CD4 and CD8 T-cells responses, with expected increased sensitivity.	benzyloxyaspartate	0-3	CD4 molecule	Homo sapiens	12-15
30786833-11	2019	Injection of TB1 (Tat-Beclin1) activated mitophagy, attenuated mitochondrial dysfunction, decreased lipid accumulation, and protected against cardiac diastolic dysfunction (end diastolic pressure-volume relationship =0.110+-0.009 in Control peptide and 0.078+-0.015 in TB1, P<0.05) during HFD feeding.	benzyloxyaspartate	13-16	tyrosine aminotransferase	Mus musculus	18-29
30348896-8	2019	Glutamate, potassium, and DL-threo-beta-benzyloxyaspartate facilitated crosslinking in the A243C/T396C transporter and this suggests that the TM4b-4c loop and beta-bridge region in TM7 were drawn into close proximity to each other in the inward- and outward-facing conformation of EAAT1.	benzyloxyaspartate	39-58	tetraspanin 16	Homo sapiens	142-146
30348896-8	2019	Glutamate, potassium, and DL-threo-beta-benzyloxyaspartate facilitated crosslinking in the A243C/T396C transporter and this suggests that the TM4b-4c loop and beta-bridge region in TM7 were drawn into close proximity to each other in the inward- and outward-facing conformation of EAAT1.	benzyloxyaspartate	39-58	solute carrier family 1 member 3	Homo sapiens	281-286
30981891-8	2019	Applying a logistic regression analysis, we found that IMID-LTBI patients had a higher probability (TB1 stimulation OR 3.32; TB2 stimulation OR 4.33) to have IFNgamma results <=0.7 IU/mL compared to NON-IMID-LTBI-subjects.	benzyloxyaspartate	100-103	interferon gamma	Homo sapiens	158-166
30364232-9	2018	In the presence of the glutamate transporter blocker TBOA (30 muM), the D-AP5-sensitive current was also significantly less in Grin2D-null mice.	benzyloxyaspartate	53-57	glutamate receptor, ionotropic, NMDA2D (epsilon 4)	Mus musculus	127-133
29463856-10	2018	Additionally, the EAAT-antagonist DL-TBOA acts differently in NPC1+/+and NPC1-/-mice.	benzyloxyaspartate	34-41	NPC1 like intracellular cholesterol transporter 1	Mus musculus	62-66
30029901-7	2018	IP-10 is increased in TB1 and TB2 tubes in subjects with active TB and LTBI compared to HD.	benzyloxyaspartate	22-25	C-X-C motif chemokine ligand 10	Homo sapiens	0-5
30029901-9	2018	Moreover, increased IP-10 in response to TB1 was found in subjects with LTBI compared to those with active TB.	benzyloxyaspartate	41-44	C-X-C motif chemokine ligand 10	Homo sapiens	20-25
29463856-10	2018	Additionally, the EAAT-antagonist DL-TBOA acts differently in NPC1+/+and NPC1-/-mice.	benzyloxyaspartate	34-41	NPC1 like intracellular cholesterol transporter 1	Mus musculus	73-77
27683885-4	2016	GluT currents were identified by using dl-threo-beta-benzyloxyaspartate (TBOA).	benzyloxyaspartate	39-71	solute carrier family 1 (glial high affinity glutamate transporter), member 3	Mus musculus	0-4
28043513-12	2016	Differently, in individuals with LTBI, the number of CD8 responders to QFT-Plus antigens increased during preventive treatment (TB1=5/11 [45%], TB2=5/11 [45%]) compared with that at the time of enrolment (TB1=1/11 [9%], TB2=1/11 [9%]).	benzyloxyaspartate	128-131	CD8a molecule	Homo sapiens	53-56
29066369-6	2018	More specifically, the Abeta impaired LTP and facilitated LTD were occluded by the selective astrocytic glutamate transporter inhibitors, TFB-TBOA.	benzyloxyaspartate	142-146	amyloid beta (A4) precursor protein	Mus musculus	23-28
28617431-5	2017	Cx36 was downregulated when nicotine or carbenoxolone was co-applied with TBOA.	benzyloxyaspartate	74-78	gap junction protein, delta 2	Rattus norvegicus	0-4
28617431-6	2017	Expression of Cx36 was preferentially observed in cytosolic rather than membrane fractions after nicotine and TBOA, suggesting protein redistribution with no change in synthesis.	benzyloxyaspartate	110-114	gap junction protein, delta 2	Rattus norvegicus	14-18
28043513-12	2016	Differently, in individuals with LTBI, the number of CD8 responders to QFT-Plus antigens increased during preventive treatment (TB1=5/11 [45%], TB2=5/11 [45%]) compared with that at the time of enrolment (TB1=1/11 [9%], TB2=1/11 [9%]).	benzyloxyaspartate	205-208	CD8a molecule	Homo sapiens	53-56
28043514-3	2016	TB1 elicits a cell-mediated immune response by CD4 T cells and TB2 elicits a response from both CD4 and CD8 T cells.	benzyloxyaspartate	0-3	CD4 molecule	Homo sapiens	47-50
28043514-3	2016	TB1 elicits a cell-mediated immune response by CD4 T cells and TB2 elicits a response from both CD4 and CD8 T cells.	benzyloxyaspartate	0-3	CD4 molecule	Homo sapiens	96-99
27683885-4	2016	GluT currents were identified by using dl-threo-beta-benzyloxyaspartate (TBOA).	benzyloxyaspartate	73-77	solute carrier family 1 (glial high affinity glutamate transporter), member 3	Mus musculus	0-4
23697999-7	2013	Three different GLT1 substrates all caused a slow TBOA-sensitive decay in the membrane current upon prolonged application, which provides support for the leak current being mediated by GLT1b itself.	benzyloxyaspartate	50-54	solute carrier family 1 member 2	Homo sapiens	16-20
26370007-7	2015	TBOA, which blocks glutamate transporters, significantly increased NMDAR-EPSCs in response to 80-Hz stimulation, particularly when metabotropic glutamate receptors (mGluRs) were also blocked, indicating that recruitment of NMDARs distal to synapses is regulated by glutamate transporters and mGluRs.	benzyloxyaspartate	0-4	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	67-72
25451797-4	2015	Inhibition by Glu of Kir4.1 mRNA expression was reversed by NMDA receptor antagonists MK-801 and AP-5 (each at 50 microM), and by a non-transportable inhibitor of Glu uptake TBOA (100 microM).	benzyloxyaspartate	174-178	potassium inwardly-rectifying channel, subfamily J, member 10	Rattus norvegicus	21-27
25547631-8	2015	We found that Abeta-induced LTP damage, which was mimicked by the Glu-reuptake inhibitor TBOA, could be rescued by blocking the NR2B subunit of NMDA receptors.	benzyloxyaspartate	89-93	glutamate ionotropic receptor NMDA type subunit 2B	Homo sapiens	128-132
24118094-7	2013	EAAT blockade with dl-threo-b-benzyloxyaspartic acid (dl-TBOA), a specific non-transportable EAAT antagonist, abolishes constitutive GAT-2/3-mediated GABA release.	benzyloxyaspartate	54-61	solute carrier family 6 (neurotransmitter transporter, betaine/GABA), member 12	Mus musculus	133-138
24118094-10	2013	In the presence of dl-TBOA, however, SNAP-5114 elicited a [Na(+) ]i decrease, demonstrating that GAT-2/3 operates in uptake mode.	benzyloxyaspartate	19-26	solute carrier family 6 (neurotransmitter transporter, betaine/GABA), member 12	Mus musculus	97-102
25981639-6	2015	The changes in SLC1A1 expression were accompanied by parallel changes in DL-Threo-beta-Benzyloxyaspartic acid (TBOA)-sensitive, UCPH101-insensitive [(3)H]-D-Aspartate uptake, consistent with increased activity of SLC1A1 (or other family members), yet not of SLC1A3.	benzyloxyaspartate	73-109	solute carrier family 1 member 1	Homo sapiens	15-21
25981639-6	2015	The changes in SLC1A1 expression were accompanied by parallel changes in DL-Threo-beta-Benzyloxyaspartic acid (TBOA)-sensitive, UCPH101-insensitive [(3)H]-D-Aspartate uptake, consistent with increased activity of SLC1A1 (or other family members), yet not of SLC1A3.	benzyloxyaspartate	111-115	solute carrier family 1 member 1	Homo sapiens	15-21
25981639-9	2015	DL-TBOA did not significantly alter cellular levels of p21, cleaved PARP-1, or phospho-Retinoblastoma protein, yet altered SLC1A1 subcellular localization, and reduced chemotherapy-induced p53 induction.	benzyloxyaspartate	0-7	solute carrier family 1 member 1	Homo sapiens	123-129
25981639-9	2015	DL-TBOA did not significantly alter cellular levels of p21, cleaved PARP-1, or phospho-Retinoblastoma protein, yet altered SLC1A1 subcellular localization, and reduced chemotherapy-induced p53 induction.	benzyloxyaspartate	0-7	tumor protein p53	Homo sapiens	189-192
25981639-11	2015	Importantly, the non-selective glutamate transporter inhibitor DL-TBOA reduces chemotherapy-induced p53 induction and augments CRC cell death induced by SN38, while attenuating that induced by oxaliplatin.	benzyloxyaspartate	63-70	tumor protein p53	Homo sapiens	100-103
25445477-2	2015	DL-threo-beta-benzyloxyaspartate (TBOA) or methionine sulfoximine (MSO) was administered intracisternally to block spinal glutamate transporter and glutamine synthetase activity in astroglia.	benzyloxyaspartate	0-32	glutamate-ammonia ligase	Rattus norvegicus	148-168
25445477-3	2015	Intracisternal administration of high dose TBOA (10 mug) produced thermal hyperalgesia in naive rats but significantly attenuated the thermal hyperalgesia in rats that had been pretreated with interleukin (IL)-1beta or Complete Freund"s Adjuvant (CFA).	benzyloxyaspartate	43-47	interleukin 1 beta	Rattus norvegicus	193-215
25445477-6	2015	Intracisternal administration of TBOA significantly increased c-Fos immunoreactivity in naive rats.	benzyloxyaspartate	33-37	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	62-67
25445477-7	2015	In contrast, intracisternal administration of TBOA significantly decreased the up-regulation of c-Fos immunoreactivity in the medullary dorsal horn of IL-1beta- and CFA-treated rats.	benzyloxyaspartate	46-50	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	96-101
25445477-7	2015	In contrast, intracisternal administration of TBOA significantly decreased the up-regulation of c-Fos immunoreactivity in the medullary dorsal horn of IL-1beta- and CFA-treated rats.	benzyloxyaspartate	46-50	interleukin 1 beta	Rattus norvegicus	151-159
24671240-8	2014	Interestingly, PVN injection of the pan-specific excitatory amino acid transporter (EAAT) inhibitor DL-threo-beta-benzyloxyaspartic acid produced smaller sympathoexcitatory and pressor responses in DH rats, which was associated with reduced glial expression of EAAT2 in PVN.	benzyloxyaspartate	100-136	solute carrier family 1 member 2	Rattus norvegicus	261-266
24336686-3	2014	In the present work, natural bond orbital (NBO) analysis shows that after doping one lithium atom into the isomeric structures Tb1 and Tb2, the electrons transfer to different regions in Tb1 and Tb2.	benzyloxyaspartate	127-130	receptor accessory protein 5	Homo sapiens	195-198
23536313-7	2013	CNS-TGF-beta1-deficient mice showed GluN2B-dependent aberrant synaptic plasticity in the CA1 area of the hippocampus similar to the glutamate transport inhibitor DL-TBOA and these mice were highly sensitive to excitotoxic injury.	benzyloxyaspartate	162-169	transforming growth factor, beta 1	Mus musculus	4-13
22561282-8	2012	In keeping with this result, the glutamate uptake blocker TBOA (5 muM) induced long-lasting synchronous discharges without suppressing the ability to produce fictive locomotion after 24 h. The novel inhibition of glutamate uptake by PJ-34 suggested that this effect may compound tests for its neuroprotective activity which cannot be merely attributed to PARP-1 block.	benzyloxyaspartate	58-62	poly (ADP-ribose) polymerase 1	Rattus norvegicus	355-361
23076103-4	2013	Inhibiting glutamate transporters by bath application of TBOA (DL-threo-beta-benzyloxyaspartic acid) prolonged the decay kinetics of both alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) and N-methyl-D-aspartate receptor (NMDAR) currents at all ages.	benzyloxyaspartate	57-61	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	216-245
23076103-4	2013	Inhibiting glutamate transporters by bath application of TBOA (DL-threo-beta-benzyloxyaspartic acid) prolonged the decay kinetics of both alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) and N-methyl-D-aspartate receptor (NMDAR) currents at all ages.	benzyloxyaspartate	57-61	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	247-252
23076103-4	2013	Inhibiting glutamate transporters by bath application of TBOA (DL-threo-beta-benzyloxyaspartic acid) prolonged the decay kinetics of both alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) and N-methyl-D-aspartate receptor (NMDAR) currents at all ages.	benzyloxyaspartate	63-99	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	216-245
23076103-4	2013	Inhibiting glutamate transporters by bath application of TBOA (DL-threo-beta-benzyloxyaspartic acid) prolonged the decay kinetics of both alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) and N-methyl-D-aspartate receptor (NMDAR) currents at all ages.	benzyloxyaspartate	63-99	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	247-252
23343894-6	2013	Application of the glutamate transporter blocker dl-threo-beta-benzyloxyaspartate (25 muM) led to a significant increase in cell participation in both layers, indicating that the concentration of extrasynaptic glutamate affects cell participation in both the INL and GCL.	benzyloxyaspartate	49-81	germ cell-less, spermatogenesis associated 1	Mus musculus	267-270
23325245-6	2013	Substitutions of several residues in TM3, TM4c, and TM7a of GLAST have detrimental effects on the inhibitory potency and/or efficacy of UCPH-101 while not affecting the pharmacological properties of (S)-glutamate or the competitive EAAT inhibitor TBOA significantly.	benzyloxyaspartate	247-251	solute carrier family 1 member 3	Homo sapiens	60-65
22326967-5	2012	Here, we investigate the possible role of mGluR on paroxysmal burst of multiple unit activities (MUA) generated in the CA1 region of developing hippocampal slices using an EAAT inhibitor, TBOA.	benzyloxyaspartate	188-192	carbonic anhydrase 1	Homo sapiens	119-122
21543591-5	2011	Soluble Abeta enhanced NR2B-mediated NMDA currents and extrasynaptic responses; these effects were mimicked by the glutamate reuptake inhibitor dl-threo-beta-benzyloxyaspartic acid.	benzyloxyaspartate	144-180	amyloid beta (A4) precursor protein	Mus musculus	8-13
21049488-7	2012	TBOA (30 muM), an inhibitor of glutamate transporter, prolonged the duration of heterosynaptic facilitation.	benzyloxyaspartate	0-4	latexin	Homo sapiens	9-12
22072505-8	2012	By employing the use-dependent NMDAR blocker (+-)MK-801 to block subsynaptic receptors, we found that although TBOA-induced spillover to extrasynaptic receptors trended to increased activation of these receptors after nerve injury, this was not significant compared with naive mice.	benzyloxyaspartate	111-115	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	31-36
21543591-5	2011	Soluble Abeta enhanced NR2B-mediated NMDA currents and extrasynaptic responses; these effects were mimicked by the glutamate reuptake inhibitor dl-threo-beta-benzyloxyaspartic acid.	benzyloxyaspartate	144-180	glutamate receptor, ionotropic, NMDA2B (epsilon 2)	Mus musculus	23-27
20220082-4	2010	Threo-beta-benzyloxyaspartate (TBOA) is a broad-spectrum glutamate transporter antagonist, affecting all three transporters [glutamate/aspartate transporter (GLAST), glutamate transporter-1 (GLT1), and excitatory amino acid carrier 1 (EAAC1)].	benzyloxyaspartate	31-35	solute carrier family 1 (glial high affinity glutamate transporter), member 3	Mus musculus	125-156
21324003-5	2011	TBOA evoked sustained network bursting, early (1 h) enhancement of the S100B immunostaining of gray matter astrocytes, and activated the motoneuronal stress ATF-3 transcription factor; 4 h later, loss (30%) of motoneuron staining ensued and pyknosis appeared.	benzyloxyaspartate	0-4	S100 calcium binding protein B	Rattus norvegicus	71-76
20423712-8	2010	In addition, ceftriaxone also induced a significant (P&lt;0.01) increase in [(3)H]-glutamate uptake, mediated by GLT-1 in glial enriched preparation, as evidenced by use of DHK and DL-threo-beta-benzyloxyaspartate (DL-TBOA).	benzyloxyaspartate	181-213	solute carrier family 1 member 2	Homo sapiens	113-118
20423712-8	2010	In addition, ceftriaxone also induced a significant (P&lt;0.01) increase in [(3)H]-glutamate uptake, mediated by GLT-1 in glial enriched preparation, as evidenced by use of DHK and DL-threo-beta-benzyloxyaspartate (DL-TBOA).	benzyloxyaspartate	215-222	solute carrier family 1 member 2	Homo sapiens	113-118
20143158-2	2010	Evidence for a functional interface between EAATs and glial fibrillary acidic protein (GFAP) relevant to astrocytic morphology led to investigations of actions of transportable (D-Aspartate (D-Asp) and (2S,3S,4R)-2-(carboxycyclopropyl)glycine (L-CCG-III)) and non-transportable (DL-threo-beta-benzyloxyaspartate (DL-TBOA)) inhibitors of Glu uptake in murine astrocytes.	benzyloxyaspartate	279-311	glial fibrillary acidic protein	Mus musculus	87-91
20143158-2	2010	Evidence for a functional interface between EAATs and glial fibrillary acidic protein (GFAP) relevant to astrocytic morphology led to investigations of actions of transportable (D-Aspartate (D-Asp) and (2S,3S,4R)-2-(carboxycyclopropyl)glycine (L-CCG-III)) and non-transportable (DL-threo-beta-benzyloxyaspartate (DL-TBOA)) inhibitors of Glu uptake in murine astrocytes.	benzyloxyaspartate	313-320	glial fibrillary acidic protein	Mus musculus	87-91
21297271-6	2011	Surprisingly, inhibiting glutamate reuptake with TBOA revealed increased glutamate reuptake activity in cortex of AbetaPP23 mice, despite decreased GLAST and GLT-1 expression, and resulted in status epilepticus in all AbetaPP23 mice, contrary to wildtype littermates.	benzyloxyaspartate	49-53	solute carrier family 1 (glial high affinity glutamate transporter), member 3	Mus musculus	148-153
21297271-6	2011	Surprisingly, inhibiting glutamate reuptake with TBOA revealed increased glutamate reuptake activity in cortex of AbetaPP23 mice, despite decreased GLAST and GLT-1 expression, and resulted in status epilepticus in all AbetaPP23 mice, contrary to wildtype littermates.	benzyloxyaspartate	49-53	solute carrier family 1 (glial high affinity glutamate transporter), member 2	Mus musculus	158-163
20220082-4	2010	Threo-beta-benzyloxyaspartate (TBOA) is a broad-spectrum glutamate transporter antagonist, affecting all three transporters [glutamate/aspartate transporter (GLAST), glutamate transporter-1 (GLT1), and excitatory amino acid carrier 1 (EAAC1)].	benzyloxyaspartate	31-35	solute carrier family 1 (glial high affinity glutamate transporter), member 3	Mus musculus	158-163
20220082-4	2010	Threo-beta-benzyloxyaspartate (TBOA) is a broad-spectrum glutamate transporter antagonist, affecting all three transporters [glutamate/aspartate transporter (GLAST), glutamate transporter-1 (GLT1), and excitatory amino acid carrier 1 (EAAC1)].	benzyloxyaspartate	31-35	solute carrier family 1 (glial high affinity glutamate transporter), member 2	Mus musculus	166-189
20220082-4	2010	Threo-beta-benzyloxyaspartate (TBOA) is a broad-spectrum glutamate transporter antagonist, affecting all three transporters [glutamate/aspartate transporter (GLAST), glutamate transporter-1 (GLT1), and excitatory amino acid carrier 1 (EAAC1)].	benzyloxyaspartate	31-35	solute carrier family 1 (glial high affinity glutamate transporter), member 2	Mus musculus	191-195
20220082-4	2010	Threo-beta-benzyloxyaspartate (TBOA) is a broad-spectrum glutamate transporter antagonist, affecting all three transporters [glutamate/aspartate transporter (GLAST), glutamate transporter-1 (GLT1), and excitatory amino acid carrier 1 (EAAC1)].	benzyloxyaspartate	31-35	solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1	Mus musculus	202-233
20220082-4	2010	Threo-beta-benzyloxyaspartate (TBOA) is a broad-spectrum glutamate transporter antagonist, affecting all three transporters [glutamate/aspartate transporter (GLAST), glutamate transporter-1 (GLT1), and excitatory amino acid carrier 1 (EAAC1)].	benzyloxyaspartate	31-35	solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1	Mus musculus	235-240
19850106-7	2010	Excitatory amino acid transporters (EAATs) regulate ambient extracellular glutamate levels that active extrasynaptic NMDA receptors, and inhibition of glutamate uptake by blocking EAATs with the non-selective transporter inhibitor dl-threo-beta-benzyloxyaspartic acid (TBOA) or the EAAT1/3 selective inhibitor l-serine O-sulfate (SOS) dephosphorylates Kv4.2 channels.	benzyloxyaspartate	231-267	solute carrier family 1 member 3	Homo sapiens	282-287
19939631-5	2010	Application of DHK or TBOA markedly reduced the frequency of epileptiform discharges in CA1 in the low magnesium and the 4-AP model while pathological activity was increased in the penicillin-model.	benzyloxyaspartate	22-26	carbonic anhydrase 1	Rattus norvegicus	88-91
19850106-7	2010	Excitatory amino acid transporters (EAATs) regulate ambient extracellular glutamate levels that active extrasynaptic NMDA receptors, and inhibition of glutamate uptake by blocking EAATs with the non-selective transporter inhibitor dl-threo-beta-benzyloxyaspartic acid (TBOA) or the EAAT1/3 selective inhibitor l-serine O-sulfate (SOS) dephosphorylates Kv4.2 channels.	benzyloxyaspartate	231-267	potassium voltage-gated channel subfamily D member 2	Homo sapiens	352-357
20953056-5	2010	However, in the presence of an uptake inhibitor, DL-TBOA, KCl stimulation showed the strongest L-glutamate flux at CA1, while TEA stimulation exhibited the strongest flux at CA3.	benzyloxyaspartate	49-56	carbonic anhydrase 1	Mus musculus	115-118
18650095-2	2008	The result of the structure-activity studies suggests that the position occupied by the aromatic ring of beta-benzylaspartate within the binding site of EAAT3 may be different from that occupied by comparable groups in previously identified inhibitors, such as L-threo-benzyloxy aspartate (TBOA).	benzyloxyaspartate	261-288	solute carrier family 1 member 1	Homo sapiens	153-158
19555648-7	2009	Abeta-facilitated LTD was mimicked by the glutamate reuptake inhibitor TBOA, including a shared dependence on extracellular calcium levels and activation of PP2B and GSK-3 signaling.	benzyloxyaspartate	71-75	amyloid beta precursor protein	Homo sapiens	0-5
20062544-5	2010	The GT inhibitor DL-threo-beta-benzyloxyaspartate greatly reduced FP recovery in CNTF rats, supporting the role of GT in CNTF-mediated neuroprotection.	benzyloxyaspartate	17-49	ciliary neurotrophic factor	Rattus norvegicus	81-85
20062544-5	2010	The GT inhibitor DL-threo-beta-benzyloxyaspartate greatly reduced FP recovery in CNTF rats, supporting the role of GT in CNTF-mediated neuroprotection.	benzyloxyaspartate	17-49	ciliary neurotrophic factor	Rattus norvegicus	121-125
19641222-5	2009	Compound TB1 was identified as a specific inhibitor for PPI of PAC3 homodimer.	benzyloxyaspartate	9-12	proteasome assembly chaperone 3	Homo sapiens	63-67
19641222-6	2009	TB1 strongly inhibited the PPI of PAC3 homodimer with an IC(50) value of 0.020 microM and did not inhibit PPI between TCF7/beta-catenin and PAC1/PAC2 even at a concentration of 250 microM.	benzyloxyaspartate	0-3	proteasome assembly chaperone 3	Homo sapiens	34-38
18674619-7	2008	The effect of inhibiting uptake is mediated primarily by the glia glutamate transporter (GLT-1) since the selective antagonist dihydrokainate (DHK) mimicked the effects of TBOA.	benzyloxyaspartate	172-176	solute carrier family 1 member 2	Rattus norvegicus	89-94
18650095-2	2008	The result of the structure-activity studies suggests that the position occupied by the aromatic ring of beta-benzylaspartate within the binding site of EAAT3 may be different from that occupied by comparable groups in previously identified inhibitors, such as L-threo-benzyloxy aspartate (TBOA).	benzyloxyaspartate	290-294	solute carrier family 1 member 1	Homo sapiens	153-158
15789377-8	2005	The glutamate transporter blocker DL-TBOA or dihydrokainate inhibited in part (approximately 35%) the GABA (10 microM)-evoked [3H]D-ASP release; this release was strongly reduced by the anion channel blockers niflumic acid and NPPB.	benzyloxyaspartate	34-41	natriuretic peptide type B	Mus musculus	227-231
18216189-4	2008	Using whole-cell recordings from rat PAG slices, we found that evoked IPSCs were reduced by the nonspecific glutamate transport blockers DL-threo-beta-benzyloxyaspartic acid (TBOA) and L-trans-pyrrolidine-2,4-dicarboxylic acid, but not by the glial GLT1-specific blocker dihydrokainate.	benzyloxyaspartate	137-173	solute carrier family 1 member 2	Rattus norvegicus	249-253
18216189-8	2008	Furthermore, the effects of both TBOA and DHPG were reduced by the cannabinoid CB1 receptor antagonist 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide (AM251).	benzyloxyaspartate	33-37	cannabinoid receptor 1	Rattus norvegicus	79-82
17634340-2	2007	We have now analyzed the consequences of their inhibition by DL-TBOA on the activity of the developing CA1 rat hippocampal network in vitro.	benzyloxyaspartate	61-68	carbonic anhydrase 1	Rattus norvegicus	103-106
17363173-6	2007	Whole-cell patch clamp recording of glutamate-induced N-methyl-d-aspartate (NMDA) currents from CA1 pyramidal neurons showed a larger potentiation of these currents after application of 15 microM dl-threo-beta-benzyloxyaspartic acid (TBOA; a potent blocker of glutamate transporters) in ceftriaxone-injected animals than in untreated animals, indicating increased glutamate transporter activity.	benzyloxyaspartate	196-232	carbonic anhydrase 1	Rattus norvegicus	96-99
17363173-6	2007	Whole-cell patch clamp recording of glutamate-induced N-methyl-d-aspartate (NMDA) currents from CA1 pyramidal neurons showed a larger potentiation of these currents after application of 15 microM dl-threo-beta-benzyloxyaspartic acid (TBOA; a potent blocker of glutamate transporters) in ceftriaxone-injected animals than in untreated animals, indicating increased glutamate transporter activity.	benzyloxyaspartate	234-238	carbonic anhydrase 1	Rattus norvegicus	96-99
17678956-9	2007	The HMGB1-evoked release of glutamate was independent on modifications of cytosolic Ca(2+) concentration, but it was blocked by dl-threo-beta-benzyloxyaspartate, suggesting the involvement of transporter-mediated release mechanisms.	benzyloxyaspartate	128-160	high mobility group box 1	Homo sapiens	4-9
16911580-4	2006	The HMGB1-evoked release of [(3)H]d-aspartate was independent of modifications of cytosolic Ca(2+) , but it was blocked by dl-threo-beta-benzyloxyaspartate (dl-TBOA), an inhibitor of glutamate transporters.	benzyloxyaspartate	123-155	high mobility group box 1	Mus musculus	4-9
16911580-4	2006	The HMGB1-evoked release of [(3)H]d-aspartate was independent of modifications of cytosolic Ca(2+) , but it was blocked by dl-threo-beta-benzyloxyaspartate (dl-TBOA), an inhibitor of glutamate transporters.	benzyloxyaspartate	157-164	high mobility group box 1	Mus musculus	4-9
16911580-5	2006	HMGB1 also stimulated the release of endogenous glutamate in a Ca(2+)-independent and dl-TBOA-sensitive manner.	benzyloxyaspartate	86-93	high mobility group box 1	Mus musculus	0-5
16137792-7	2005	Platelet activation by thrombin caused an increase in glutamate uptake, which could be inhibited by TBOA and the EAAT2 inhibitor DHK.	benzyloxyaspartate	100-104	coagulation factor II, thrombin	Homo sapiens	23-31
16169022-4	2005	In acute hippocampal slices, photolysis of Ncm-D-aspartate by brief (1 ms) exposure to UV light elicited rapidly activating inward currents in astrocytes that were sensitive to inhibition by the glutamate transporter antagonist DL-threo-beta-benzyloxyaspartic acid (TBOA).	benzyloxyaspartate	228-264	CWC22 spliceosome associated protein homolog	Homo sapiens	43-46
16169022-4	2005	In acute hippocampal slices, photolysis of Ncm-D-aspartate by brief (1 ms) exposure to UV light elicited rapidly activating inward currents in astrocytes that were sensitive to inhibition by the glutamate transporter antagonist DL-threo-beta-benzyloxyaspartic acid (TBOA).	benzyloxyaspartate	266-270	CWC22 spliceosome associated protein homolog	Homo sapiens	43-46
16026460-8	2005	Finally, intrahippocampal microinjection of WAY-855 (200 and 300 nmol) in vivo resulted in marginal damage compared with TBOA (20 and 200 nmol), which killed the majority of both CA1-4 pyramidal cells and dentate gyrus granule cells.	benzyloxyaspartate	121-125	carbonic anhydrase 1	Rattus norvegicus	179-182
17498876-7	2007	The data suggest that TBOA-sensitive uptake mechanisms are able to maintain a steep concentration gradient of glutamate to such a degree that a CA1 neuron at a depth of 30 microm is exposed to low extracellular glutamate levels that are not sufficient to induce a detectable activation of group I mGluRs (&lt; 2 microM).	benzyloxyaspartate	22-26	carbonic anhydrase 1	Homo sapiens	144-147
16904707-9	2007	In comparison, LTD was unaffected by Ro (5 microM) even in the presence of a glutamate uptake inhibitor threo-beta-benzylaspartic acid (TBOA) to increase the concentration of glutamate at NR2B containing receptors.	benzyloxyaspartate	136-140	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	188-192
16775144-4	2006	After the application of PMB-TBOA, slow-rising CF-EPSCs were newly detected in WT mice, and their rise and decay kinetics were different from those of conventional fast-rising CF-EPSCs but similar to those of atypical CF-EPSCs in GLAST-deficient mice.	benzyloxyaspartate	29-33	solute carrier family 1 (glial high affinity glutamate transporter), member 3	Mus musculus	230-235
15215288-4	2004	NMDA and inhibition of glutamate transporters with DL-threo-beta-benzyloxyaspartic acid (TBOA) increased the frequency of miniature IPSCs (mIPSCs) by enhancing presynaptic NMDA receptor (NMDAR) activation, whereas inhibition of cystine-glutamate antiporters had no effect on mIPSCs.	benzyloxyaspartate	51-87	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	172-185
15695241-3	2005	We monitored tonic glutamate release in area CA1 of hippocampal slices by measuring the glutamate receptor-mediated current evoked in pyramidal cells on block of Na(+)-dependent glutamate uptake with dl-threo-beta-benzyloxyaspartate (TBOA).	benzyloxyaspartate	200-232	carbonic anhydrase 1	Rattus norvegicus	45-48
15215288-4	2004	NMDA and inhibition of glutamate transporters with DL-threo-beta-benzyloxyaspartic acid (TBOA) increased the frequency of miniature IPSCs (mIPSCs) by enhancing presynaptic NMDA receptor (NMDAR) activation, whereas inhibition of cystine-glutamate antiporters had no effect on mIPSCs.	benzyloxyaspartate	51-87	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	187-192
15215288-4	2004	NMDA and inhibition of glutamate transporters with DL-threo-beta-benzyloxyaspartic acid (TBOA) increased the frequency of miniature IPSCs (mIPSCs) by enhancing presynaptic NMDA receptor (NMDAR) activation, whereas inhibition of cystine-glutamate antiporters had no effect on mIPSCs.	benzyloxyaspartate	89-93	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	172-185
15215288-4	2004	NMDA and inhibition of glutamate transporters with DL-threo-beta-benzyloxyaspartic acid (TBOA) increased the frequency of miniature IPSCs (mIPSCs) by enhancing presynaptic NMDA receptor (NMDAR) activation, whereas inhibition of cystine-glutamate antiporters had no effect on mIPSCs.	benzyloxyaspartate	89-93	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	187-192
15215288-8	2004	Repetitive stimulations of climbing fibers resulted in a NMDAR-dependent reduction of sIPSC amplitude, and this effect was enhanced by TBOA even when postsynaptic glutamate transporters were blocked.	benzyloxyaspartate	135-139	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	57-62
15140926-6	2004	However, inhibition of all glutamate transporters with TBOA (DL-threo-b-benzyloxyaspartic acid) increased mGluR1 EPSCs &gt;15-fold, indicating that additional transporters also shape activation of these receptors.	benzyloxyaspartate	55-59	glutamate receptor, metabotropic 1	Mus musculus	106-112
14992289-5	2004	In contrast, transport was inhibited by GLAST-1 transportable substrates threo-hydroxyaspartate and aspartate-beta-hydroxamate, but not by the nontransportable inhibitors trans-pyrrolidine dicarboxylate or DL-threo-beta-benzyloxyaspartic acid.	benzyloxyaspartate	206-242	solute carrier family 1 member 3	Homo sapiens	40-47
15044631-7	2004	Electrophysiological analyses revealed that TBOA analogs block the transport-associated currents in all five EAAT subtypes and also block leak currents in EAAT5.	benzyloxyaspartate	44-48	solute carrier family 1 (glutamate transporter), member 7	Mus musculus	155-160
12154181-7	2002	The specific inhibitor DL-threo-beta-benzyloxyaspartate (TBOA) reduced the EAAT1-specific L(p) to 72 %.	benzyloxyaspartate	23-55	solute carrier family 1 member 3	Homo sapiens	75-80
12154181-7	2002	The specific inhibitor DL-threo-beta-benzyloxyaspartate (TBOA) reduced the EAAT1-specific L(p) to 72 %.	benzyloxyaspartate	57-61	solute carrier family 1 member 3	Homo sapiens	75-80
10841893-9	2000	The amino acid data are interpreted as indicating that aspartate and glutamate releases were reduced as a consequence of DL-TBOA inhibition of reversed transport by high-affinity, Na-dependent carriers, predominantly involving the glial EAAT 2 transporter.	benzyloxyaspartate	121-128	solute carrier family 1 member 2	Rattus norvegicus	237-243
10411944-3	1999	By using the N-methyl-D-aspartate receptors of patched CA3 hippocampal neurons as "glutamate sensors," we observed that application of TBOA onto organotypic hippocampal slices led to a rapid increase in extracellular glutamate concentration.	benzyloxyaspartate	135-139	carbonic anhydrase 3	Homo sapiens	55-58
12832505-8	2003	It was inhibited by the nontransportable glutamate transporter antagonist sc-threo-beta-benzyloxyaspartate (TBOA) but was insensitive to the GLT1/EAAT2 subtype-selective antagonist dihydrokainate and was affected by extracellular pH buffering.	benzyloxyaspartate	108-112	solute carrier family 1 member 3	Rattus norvegicus	41-62
11973429-6	2002	Additional block of glial glutamate uptake with TBOA (dl-threo-beta-benzyloxyaspartate), a nontransportable and potent inhibitor, dramatically reduced the latency to onset of AD and abolished the difference between wild-type mice and EAAC1-/- mice.	benzyloxyaspartate	48-52	solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1	Mus musculus	234-239
11973429-6	2002	Additional block of glial glutamate uptake with TBOA (dl-threo-beta-benzyloxyaspartate), a nontransportable and potent inhibitor, dramatically reduced the latency to onset of AD and abolished the difference between wild-type mice and EAAC1-/- mice.	benzyloxyaspartate	54-86	solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1	Mus musculus	234-239
21669728-2	2002	Here we present a detailed characterization of the ba1 mutant phenotype, including scanning electron microscopy of developing inflorescences, in situ hybridization analysis using a meristem marker, molecular mapping, and genetic analysis demonstrating an epistatic relationship between ba1 and teosinte branched1 (tb1).	benzyloxyaspartate	314-317	barren stalk 1	Zea mays	51-54
11599006-12	2001	In addition, DL-threo-beta-benzyloxyaspartate (DL-TBOA) also blocked the BDNF-mediated glutamate release, suggesting that reverse transport of glutamate may be involved.	benzyloxyaspartate	13-45	brain derived neurotrophic factor	Homo sapiens	73-77
11599006-12	2001	In addition, DL-threo-beta-benzyloxyaspartate (DL-TBOA) also blocked the BDNF-mediated glutamate release, suggesting that reverse transport of glutamate may be involved.	benzyloxyaspartate	47-54	brain derived neurotrophic factor	Homo sapiens	73-77
9463476-2	1998	DL-TBOA inhibited the uptake of [14C]glutamate in COS-1 cells expressing the human excitatory amino acid transporter-1 (EAAT1) (Ki = 42 microM) with almost the same potency as DL-threo-beta-hydroxyaspartate (Ki = 58 microM).	benzyloxyaspartate	0-7	solute carrier family 1 member 3	Homo sapiens	83-118
9463476-2	1998	DL-TBOA inhibited the uptake of [14C]glutamate in COS-1 cells expressing the human excitatory amino acid transporter-1 (EAAT1) (Ki = 42 microM) with almost the same potency as DL-threo-beta-hydroxyaspartate (Ki = 58 microM).	benzyloxyaspartate	0-7	solute carrier family 1 member 3	Homo sapiens	120-125
9463476-3	1998	With regard to the human excitatory amino acid transporter-2 (EAAT2), the inhibitory effect of DL-TBOA (Ki = 5.7 microM) was much more potent than that of dihydrokainate (Ki = 79 microM), which is well known as a selective blocker of this subtype.	benzyloxyaspartate	95-102	solute carrier family 1 member 2	Homo sapiens	25-60
9463476-3	1998	With regard to the human excitatory amino acid transporter-2 (EAAT2), the inhibitory effect of DL-TBOA (Ki = 5.7 microM) was much more potent than that of dihydrokainate (Ki = 79 microM), which is well known as a selective blocker of this subtype.	benzyloxyaspartate	95-102	solute carrier family 1 member 2	Homo sapiens	62-67